- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03892408
High-flow Nasal Oxygen During Rigid Bronchoscopy Under General Anesthesia: a Randomized Controlled Trial
March 28, 2019 updated by: Yonsei University
The aim of this study is to evaluate the effect of high-flow nasal cannula oxygen administration on apnea in patients undergoing general anesthesia with rigid bronchoscopy compared with standard anesthesia methods.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
56
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 120-752
- Recruiting
- Department of Anesthesiology and Pain Medicine , Anesthesia and Pain Research Institute, Yonsei University College of Medicine
-
Contact:
- Young Jun Oh, M.D., PhD.
- Phone Number: 82-2-2224-4428
- Email: yjoh@yuhs.ac
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 1. Patients undergoing general anesthesia with stent placement or bougination, biopsy or removal of a foreign body or a mass through a rigid bronchoscope
- 2. Patients aged 19 or older who meet American Society of Anesthesiologists (ASA) physical class 2-4
Exclusion Criteria:
- 1. Patients with dementia or cognitive impairment
- 2. pregnant women
- 3. Patients undergoing extracorporeal membrane oxygenation (ECMO)
- 4. Patients with active nasal bleeding), severe nasal obstruction, recent nasal trauma of surgery
- 5. Patients with current maxillofacial trauma or basal skull fracture
- 6. Patients who had previously undergone rigid bronchoscopy / surgery
- 7. If the subject includes a person who can not read the written consent (eg, illiterate, foreigner, etc.)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Optiflow
100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand)
|
supply of 100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand) plus standard oxygen supply through rigid bronchoscope during apnea period.
|
No Intervention: Standard
standard anesthesia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the lowest oxygen saturation
Time Frame: apnea period during the rigidbroscopic procedure/surgery
|
the lowest value of oxygen saturation measured percutaneously at extremity.
|
apnea period during the rigidbroscopic procedure/surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hypoxia occurs the first time
Time Frame: intraoperative (The time taken to reach the point at which peripheral oxygen saturation fell below 90 for the first time immediately after the onset of apnea)
|
intraoperative (The time taken to reach the point at which peripheral oxygen saturation fell below 90 for the first time immediately after the onset of apnea)
|
End-tidal carbon dioxide partial pressure
Time Frame: Intraoperative (end-tidal CO2 partial pressure after 3 consecutive breaths after intubation or insertion of laryngeal mask following end of apnea)
|
Intraoperative (end-tidal CO2 partial pressure after 3 consecutive breaths after intubation or insertion of laryngeal mask following end of apnea)
|
Arterial oxygen / carbon dioxide partial pressure
Time Frame: shortly before start of apnea (within 30 seconds)
|
shortly before start of apnea (within 30 seconds)
|
Arterial oxygen / carbon dioxide partial pressure
Time Frame: shortly after end of apnea (within 30 seconds)
|
shortly after end of apnea (within 30 seconds)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 21, 2019
Primary Completion (Anticipated)
March 1, 2021
Study Completion (Anticipated)
March 1, 2021
Study Registration Dates
First Submitted
March 26, 2019
First Submitted That Met QC Criteria
March 26, 2019
First Posted (Actual)
March 27, 2019
Study Record Updates
Last Update Posted (Actual)
April 1, 2019
Last Update Submitted That Met QC Criteria
March 28, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1-2019-0005
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tumor
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyActive, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation TumorKorea, Republic of
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
National Health Research Institutes, TaiwanNational Cheng-Kung University HospitalRecruiting
-
Elpiscience Biopharma, Ltd.Shanghai Junshi Bioscience Co., Ltd.RecruitingNeoplasms | Solid Tumor | Malignant TumorChina
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyRecruitingSolid Tumor, Adult | Refractory TumorUnited States
Clinical Trials on Optiflow ™
-
Catholic University of the Sacred HeartCompletedRespiratory FailureItaly
-
Papworth Hospital NHS Foundation TrustCompletedCardiac SurgeryUnited Kingdom
-
University Hospital, MontpellierFisher and Paykel HealthcareCompletedHypercapnic Respiratory Failure | Acute Cardiogenic Pulmonary EdemaFrance
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Changi General HospitalCompleted
-
Cliniques universitaires Saint-Luc- Université...Completed
-
NHS Greater Glasgow and ClydeFisher and Paykel HealthcareUnknown
-
University Health Network, TorontoUnknown
-
University Hospital, GhentCompleted
-
Nantes University HospitalCompletedHypoxemic Acute Respiratory FailureFrance